<DOC>
	<DOCNO>NCT02737605</DOCNO>
	<brief_summary>The purpose study assess effect esketamine QT/QTc interval electrocardiogram ( ECG ) morphology therapeutic exposure esketamine noresketamine ( intranasal administration ) supratherapeutic exposure esketamine ( intravenous administration ) healthy adult .</brief_summary>
	<brief_title>A Study Evaluate Effects Esketamine Cardiac Repolarization Healthy Participants</brief_title>
	<detailed_description>This randomize ( study medication assign participant chance ) , placebo- positive-controlled , double-blind ( Periods 1 3 ) , open-label ( Period 4 ) , single-dose , crossover study 60 healthy adult . The study Screening Phase Treatment Phase . Participants randomly assign 1 6 treatment sequence group receive 4 treatment ( 1 treatment per period ) ; Treatment A ( intravenous placebo , Intranasal placebo Oral placebo tablet match moxifloxacin tablet ) , Treatment B ( intravenous placebo , 84 milligram ( mg ) intranasal esketamine 4 device , 28 mg esketamine Oral placebo tablet match moxifloxacin tablet ) , Treatment C ( intravenous placebo , Intranasal placebo 400 mg oral moxifloxacin tablet ) Treatment D ( 0.8 milligram per kilogram intravenous esketamine , Intranasal placebo Oral placebo tablet match moxifloxacin tablet ) . The first 3 period double-blinded fourth period open-label . Periods 1 , 2 , 3 , 4 separate 5 7 day . Primarily effect esketamine QT/QTc interval electrocardiogram ( ECG ) morphology evaluate . Safety participant monitor throughout study .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Signed informed consent document indicate understand purpose procedure require study willing participate study Body mass index ( BMI ) 18 30 kilogram ( kg ) /meter square ( [ ] ^2 ) ( inclusive ) , body weight less 50 kilogram ( kg ) Women use oral contraceptive must agree use additional birth control method study 1 month receive last dose study drug next menstrual period A woman childbearing potential , must negative serum betahuman chorionic gonadotropin ( hCG ) pregnancy test Screening negative urine pregnancy test Day 1 first treatment period A man , must agree use adequate contraception method deem appropriate investigator ( example , vasectomy , doublebarrier , partner use effective contraception ) donate sperm study 3 month receive last dose study drug Participant current diagnosis psychotic disorder major depressive disorder ( MDD ) psychosis , bipolar related disorder , intellectual disability , borderline personality disorder , antisocial personality disorder Clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , gastrointestinal disease , hypertension , vascular disorder , sleep apnea , myasthenia gravis , illness investigator considers exclude participant could interfere interpretation study result History additional risk factor torsade de pointes presence family history Short QT Syndrome , Long QT Syndrome , sudden unexplained death young age ( less than/equal 40 year ) , drown sudden infant death syndrome first degree relative ( , biological parent , sibling , child ) Clinically significant abnormal value hematology , clinical chemistry urinalysis Screening admission study center first treatment period deem appropriate investigator . Electrolytes ( potassium , magnesium , calcium ) within reference range laboratory Clinically significant abnormal physical examination , vital sign , 12 lead electrocardiogram ( ECG ) Screening admission study center first treatment period deem appropriate investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Esketamine</keyword>
	<keyword>Healthy</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Electrocardiogram</keyword>
	<keyword>Repolarization</keyword>
</DOC>